Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 7, 2026, addresses a material event regarding the Company's compliance with Nasdaq listing standards. The report details the resolution of a stockholders' equity deficiency that existed as of December 31, 2025.
Key Financial Metrics
- Stockholders' Deficit (Dec 31, 2025): Approximately $18.7 million.
- Nasdaq Minimum Equity Requirement: $2.5 million.
- Projected Stockholders' Equity (Apr 7, 2026): Exceeds $2.5 million following recent transactions.
- Capital Inflows Identified:
- $16.0 million: Non-dilutive capital from License Agreement with Napo Pharmaceuticals, Woodward Specialty LLC, and Future Pak.
- $3.0 million: Received by Napo following termination of a buy-back provision.
- $1.0 million: Inventory purchase by Woodward under the Supply Agreement.
- $2.0 million: Expected upon satisfaction of Third Party Replacement MSA Conditions.
- $1.2 million: Expected from the sale of Mytesi Product under a Firm Order.
- $0.2 million: Net sales of Mytesi (Jan 1–11, 2026).
- $0.2 million: Grant revenue awarded to the Company.
- $3.4 million: Gain on extinguishment of debt owed to affiliates of Chicago Venture Partners, L.P.
Material Changes
The primary material change is the transition from a stockholders' deficit of $18.7 million to a projected positive equity position exceeding $2.5 million. This shift is driven by a combination of non-dilutive capital raises, asset sales, debt extinguishment gains, and grant revenue, effectively reversing the non-compliance with Nasdaq Listing Rule 5550(b)(1).
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the Company's belief that its equity will exceed the $2.5 million threshold. The Company notes that actual results may differ materially from expectations. Specific contingencies include the satisfaction of Third Party Replacement MSA Conditions for the $2.0 million receipt and the execution of the Firm Order for the $1.2 million receipt. Investors are directed to the Form 10-K for detailed risk factors.
Investor Verification Checklist
- Confirm the final audited stockholders' equity balance as of April 7, 2026, to verify Nasdaq compliance.
- Verify the receipt of the $2.0 million contingent on Third Party Replacement MSA Conditions.
- Confirm the execution and payment status of the $1.2 million Firm Order for Mytesi Product.
- Review the details of the debt extinguishment gain of $3.4 million in the accompanying Form 10-K.
- Monitor for any Nasdaq communications regarding the reinstatement of listing status.